candesartan has been researched along with gw9662 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, H; Yoshida, K | 1 |
| Im, DS; Son, SE | 1 |
2 other study(ies) available for candesartan and gw9662
| Article | Year |
|---|---|
Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Benzimidazoles; Benzoates; Biphenyl Compounds; Disease Models, Animal; Hyperlipidemias; Male; Nitric Oxide; PPAR gamma; Rabbits; Telmisartan; Tetrazoles; Up-Regulation | 2008 |
Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Benzoates; Cell Differentiation; Dermatitis, Atopic; Humans; Imiquimod; PPAR gamma; Psoriasis; Skin; Telmisartan; Th17 Cells | 2023 |